Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Drug Combo Could Prevent Head and Neck Cancer in High-Risk Patients

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Print article
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
A new combination of drugs has demonstrated potential in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck.

“Squamous cell carcinoma of the head and neck [SCCHN] is the most common type of head and neck cancer,” said Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology at Emory University School of Medicine (Atlanta, GA, USA), and director of the Cancer Chemoprevention Program at Winship Cancer Institute at Emory University. “The survival rate for patients with SCCHN is very poor. An effective prevention approach is desperately needed, especially since we can identify patients who are at extremely high risk: those with advanced oral precancerous lesions.”

Based on earlier research suggesting a role for epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in promoting SCCHN, Dr. Shin and colleagues believed combining an EGFR inhibitor and a COX-2 inhibitor could provide an effective chemopreventive approach. They found that the combination of the EGFR inhibitor erlotinib and the COX-2 inhibitor celecoxib was more effective for inhibiting the growth of human SCCHN cell lines compared with either drug alone. Moreover, treating mice with the drug combination prior to transplanting them with human SCCHN cells more effectively suppressed cancer cell growth than did pretreating the mice with either drug alone.

Dr. Shin and colleagues, based on these preclinical analyses, initiated a phase I chemoprevention trial. Eleven patients with advanced oral precancerous lesions were assigned to treatment with erlotinib and celecoxib. Tissue samples from the patients were taken and assessed pathologically at 3, 6, and 12 months after the start of therapy. Biopsies at baseline and follow-up were available for seven patients. The study’s findings, which included preclinical and clinical analyses, were published February 2013 in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Pathologic examination of the biopsies indicated that three of the seven patients had a complete pathologic response; that is, there was no longer evidence of the precancerous lesions in the follow-up biopsy sample. Among the other patients, two had a partial pathologic response and two had progressive disease. “Finding that this drug combination caused some advanced premalignant lesions to completely disappear was great news,” remarked Dr. Shin. “Advanced premalignant lesions rarely regress, so our data are proof-of-principle that a combination chemopreventive strategy with molecularly targeted agents is possible.”

Several patients dropped out of the trial because of severe adverse side effects, according to Dr. Shin. “Prevention is not achieved through short-term treatment,” he said. “So, we need to investigate the safety and toxicity of this combination further before planning a large-scale trial. We are also looking to combination therapies using less toxic or nontoxic agents, such as natural compounds.”

Related Links:

Emory University School of Medicine




Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.